Lantheus Medical Imaging is highlighting two PET studies that will be presented at the upcoming Society for Nuclear Medicine and Molecular Imaging (SNMMI) 2023 annual meeting.
Both involve use of the company's PET radiotracer Pylarify, a prostate-specific membrane antigen (PSMA) tracer approved in the U.S. for diagnosing advanced prostate cancer.
- "Use of aPROMISE as an artificial intelligence software to automate and standardize quantitative heterogeneity of PSMA and FDG PET/CT in patients with mCRPC prior to PSMA radioligand therapy: a proof-of-concept study" will be presented on 25 June at 11 a.m. CT.
- "Total and Anatomically Contextualized Quantitative F-18 DCFPyL PET at biochemical recurrence predicts subsequent biochemical progression-free survival in prostate cancer patients" will be presented on 26 June at 11:15 a.m. CT.
The meeting will be held from 24 to 27 June in Chicago.
